Canada’s Drug Agency (CDA-AMC) is urging that Yorvipath (palopegteriparatide) — an injection therapy approved in the country earlier this year — be reimbursed for eligible adults with hard-to-treat chronic hypoparathyroidism. The agency, responsible for aligning drug policy across Canada, has recommended that patients prescribed Yorvipath be eligible for…
Discussion
It’s easy to get lost in the fun of summer, especially when on vacation. This was extra true for me when it came time for my annual trip with my lifelong best friends. Having missed last year due to my grandma’s memorial, I’d been counting the days to when we…
Discussion
Before my flare-up in June, I was invited to join my favorite local bookstore, Sidetrack Bookshop, to do an author event for the city’s Pride weekend. The store is in Royal Oak, Michigan, which celebrates Pride at the end of July, dovetailing with Disability Pride Month. I…
Discussion
The use of teriparatide, a lab-made version of the parathyroid hormone — low levels of which lead to hypoparathyroidism — should not replace supplement therapy in children with the rare condition, but may benefit young patients who don’t respond well to standard care. That’s the key takeaway from…
Get regular updates to your inbox.
